Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
12/2003
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099798A1 Morpholinylmethylureas ccr-3 receptor antagonist
12/04/2003WO2003099796A1 Protein kinase inhibitors
12/04/2003WO2003099781A2 METHODS FOR THE IDENTIFICATION OF IKKα FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
12/04/2003WO2003099771A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003WO2003099765A1 β-ALANINE DERIVATIVE AND USE THEREOF
12/04/2003WO2003099764A1 ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
12/04/2003WO2003099759A1 Preparation and application of transhintotalphenolic acid
12/04/2003WO2003099334A1 Topically applicable pharmaceutical preparation
12/04/2003WO2003099326A1 Novel uses of parapoxvirus preparations
12/04/2003WO2003099284A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003WO2003099278A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
12/04/2003WO2003099270A1 Methods of treating allergic reactions
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003066598A9 Novel anhydrous amorphous forms of montelukast sodium salt
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063794A3 2,4-pyrimidinediamine compounds and their uses
12/04/2003WO2003062200A3 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
12/04/2003WO2003057169A3 4-dedimethylamino tetracycline compounds
12/04/2003WO2003045917B1 Ccr-3 receptor antagonists vii
12/04/2003WO2003018019A3 New use of cyclic compounds
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003US20030225287 Synthesis of chiral 2-alkyl amino acids
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
12/04/2003US20030225120 Dihydropyridine soft drugs, and related compositions and methods
12/04/2003US20030225106 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
12/04/2003US20030225103 Method of using diketopiperazines and composition containing them
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225092 E.g., 6-Benzo(1,3)dioxol-5-yl-10-hydroxy-2-methyl-2,3,6,7,12, 12a-hexa-hydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225086 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225063 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225062 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225057 3-Benzoazepine derivatives
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225038 Adenosine receptor antagonists and methods of making and using the same
12/04/2003US20030225034 Preventing and treating vaginitis, preterm labor, post-operative pelvis infection, infertility, and sexually transmitted diseases with surfactant lipids, especially surfactant protein A
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224072 Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions
12/04/2003US20030224008 Novel uses for anti-malarial therapeutic agents
12/04/2003US20030224000 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487441A1 Novel uses of parapoxvirus preparations
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1366771A2 Use of the neurotoxic compnent of botulinum toxins as a medicament
12/03/2003EP1366770A2 Use of botulinum toxin for treating muscle-associated pain
12/03/2003EP1366175A2 Multifunctional protease inhibitors and their use in treatment of disease
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366146A2 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366075A2 New interferon beta-like molecules
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366025A1 Agonists of beta-adrenoceptors
12/03/2003EP1366020A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1365800A2 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/03/2003EP1365798A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
12/03/2003EP1365791A2 Cyclosporins for the treatment of respiratory diseases
12/03/2003EP1365778A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno
12/03/2003EP1365777A2 Proteoglycan compositions for treatment of inflammatory conditions
12/03/2003EP1365767A2 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
1 ... 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 ... 878